I think progress is good. They have recruited within 3 months of schedule and more importantly, recruited exactly who they wanted (according to stamler at AAN) (? Possibly due to natural history study insights)
I got the gist of Ashley Palls poster but have a average background in chemistry so some of it is over my head. As expected though, she presented a case that supports ATH434 for FA (otherwise why would alterity go public with research like this?)
why bring in FA now is my query though. Is it a backup in case MSA doesn't work out (this is my baggage from another biotech that rug pulled its primary indication straight after announcing a 2nd). That looks unlikely here at this point in the game. Maybe the FA research is too compelling to not publish...
i think the small cap US biotech market had jitters last night after Annovis disappointed with is phase II/III. (Patient selection anyone??)
anyway, high risk, high reward. Imo
ATH Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)